What Scinvivo does

Scinvivo B.V. is a Dutch medical device startup founded in 2016 and headquartered in Eindhoven, Netherlands, developing optical coherence tomography (OCT) imaging technology for bladder cancer diagnostics. The company's core product, the Lumante Imaging System, combines a single-use forward-looking OCT catheter (2.5mm outer diameter, 7.5 Fr; 5mm field of view; 2-3mm imaging depth; refresh rate above 60Hz) with a base station and proprietary S-Vision software to provide real-time, micrometer-resolution cross-sectional visualization of bladder tissue structure during standard cystoscopy procedures. The technology is built on an inherited portfolio of approximately 30 MEMS mirror and optical system patents transferred from Innoluce (a Philips spin-off acquired by Infineon in 2016), and addresses a documented clinical gap in which current cystoscopy reveals only the bladder wall surface, missing up to 30% of cancerous tissue and producing false positives in 36-52% of healthy tissue cases.

The company is pre-commercial: the Lumante Imaging System received FDA Breakthrough Device Designation in January 2025 but does not yet hold CE or FDA market clearance. Scinvivo's planned commercial model is a razor-and-blade combination of capital equipment (base station) sales and disposable catheter consumables (target catheter cost below €200 at 10,000+ units/year), targeting urologists and hospital systems across Europe and the US as primary customers, with a strategic channel into Japan through investor Santec OIS Corporation. An early adopter program with 10 Key Opinion Leader urologists across six European countries (NL, DE, UK, DK, ES, FR) is in place, and a dedicated clinical-trial recruitment form on the website is filling the evidence base for regulatory submissions. Additional pipeline indications (intestinal and lung diagnostics) and a photonics-based localization feature enabling robotic surgery are referenced as roadmap extensions.

The company has raised over €8M cumulatively through a mix of grants, debt, and equity, with the €4.7M Series A closed in February 2024 led by Santec OIS and NLC Health Impact Fund. The team consists of approximately 10-15 members; recent additions include CCO Liesbeth Geerts (October 2024, ex-Philips MRI), Principal OCT Architect Dirk Faber (2024, ex-Amsterdam UMC), CFO Maarten Haast (February 2025, ex-Stryker EEMEA CFO), and Medical Application Engineer Jesper Schouren (2025), signaling a deliberate transition from R&D toward commercial readiness. AI is positioned as a featured but not core differentiator, used in combination with the OCT platform to distinguish benign from malignant tissue types.

Name

Scinvivo

Legal name

Scinvivo B.V.

Website

https://scinvivo.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Scinvivo is a Dutch MedTech startup developing the Lumante Imaging System, an OCT-based catheter enabling real-time bladder cancer diagnostics during cystoscopy. The pre-commercial company targets urologists and hospital systems across Europe, the US, and Japan; FDA Breakthrough Device Designation was received in January 2025.

Ownership category

akta.pro rank

Product category

Medical Imaging Equipment

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)

akta.pro secondary industry

Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG)

Keywords

• OCT imaging platform
• Bladder cancer diagnostics
• Minimally invasive imaging
• Optical biopsy technology
• Medical catheter imaging

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. OCT Imaging Platform — Hardware Sales: Product offering consists of a single-use catheter and a base station. The catheter is sold as a disposable consumable while the base station is a capital equipment purchase. Target cost price per catheter is below €200 at production volumes of 10,000+ units/year.
2. Clinical Trial & Certification Services (Future): As a pre-commercial medical device company, Scinvivo currently derives no product revenue. The company is in clinical trial and CE/FDA certification phase, with commercial revenue expected after regulatory approvals.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Scinvivo develops and sells the Lumante Imaging System, an optical biopsy platform for bladder cancer diagnostics. The system comprises a forward-looking single-use OCT catheter (2.5 mm outer diameter, 5 mm field of view, 2–3 mm depth) paired with a base station and the proprietary S-Vision software. It enables real-time, minimally invasive visualization and local staging of bladder tissue at micrometer resolution during standard cystoscopy procedures. The product is intended for urologists and hospital systems performing bladder cancer diagnosis, staging, and follow-up monitoring.

Product overview

Scinvivo's product offering consists of the Lumante Imaging System, a comprehensive OCT imaging platform for bladder cancer diagnostics. The system comprises three integrated components: a forward-looking single-use OCT catheter (2.5mm diameter, 5mm field of view, 2-3mm depth), a base station for data processing, and S-Vision proprietary software for image capture and visualization. Combined with AI, the platform enables real-time distinction between benign and malignant tissue types with microscopic resolution. The Lumante system has received FDA Breakthrough Device Designation.

Differentiator

Problem solved

Functional benefit

Products and services

• Lumante Imaging System The Lumante Imaging System is Scinvivo's integrated OCT imaging platform for bladder cancer diagnostics. It combines a forward-looking single-use OCT catheter, a base station, and the S-Vision software to deliver real-time, minimally invasive visualization and local staging of bladder cancer during cystoscopy. The system received FDA Breakthrough Device Designation for its potential to improve cancer diagnostics.
• Forward-Looking OCT Catheter A single-use forward-looking OCT catheter with an outer diameter of 2.5 mm (7.5 Fr), a 5 mm field of view, and 2–3 mm imaging depth. Features a working distance of approximately 10 mm from tip to tissue and a refresh rate exceeding 60 Hz to minimize motion artifacts. Designed for single-use to prevent cross-patient infections. It is the consumable component of the Lumante Imaging System, with a target cost price below €200 at production volumes of 10,000+ units per year.
• Base Station The hardware base station is the capital equipment component of the Lumante Imaging System. It pairs with the single-use OCT catheter to capture and process OCT imaging data and hosts the S-Vision software for image visualization and enhancement.
• S-Vision Software S-Vision is the proprietary software developed by Scinvivo and installed on the base station. It captures and visualizes high-quality OCT images using filter techniques, interlacing, and image enhancement. Supports snapshot image saving with location information and real-time movie recording for desk analysis, including tumor size estimation and application of enhanced filter techniques.

Quantifiable outcome

• Faster diagnosis increases survival chances up to 30%
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Six partnerships are on record, tiered minor.

• LuxfluxminorStrategic or Co-development Partner · 15 October 2021Luxflux, an R&D company optimizing optics technology with special software and camera systems for microscopy solutions, is part of the Eurostars OCT-DETECT consortium. Their expertise complements Scinvivo's OCT catheter with enhanced imaging processing capabilities.
• Amsterdam UMCminorStrategic or Co-development Partner · 15 October 2021Amsterdam UMC, one of the largest hospitals and research centres in the Netherlands with a long track record in high-impact OCT publications, is part of the Eurostars OCT-DETECT consortium. They handle clinical validation and first-in-human feasibility studies for the OCT catheter.
• Eberhard-Karls University Tübingen (University Hospital Tübingen)minorStrategic or Co-development Partner · 15 October 2021University Hospital Tübingen, one of 33 university hospitals in Germany and a renowned centre for urologic surgery, is part of the Eurostars OCT-DETECT consortium providing clinical expertise and urological surgical knowledge.
• BrucominorStrategic or Co-development Partner · 7 September 2020Bruco, an SME, is developing the prototype ASIC (Application-Specific Integrated Circuit) — an essential electronic component for the OCT catheter — as part of the OPOost-subsidized Next Gen In-Vivo Cancer Diagnostics project.
• RadboudumcminorStrategic or Co-development Partner · 7 September 2020Radboudumc researches possible areas of application for the OCT catheter and conducts valorisation studies in tissues and patients, as part of the OPOost-subsidized Next Gen In-Vivo Cancer Diagnostics project involving 4 consortium partners.
• University of Twente (UTwente)minorStrategic or Co-development Partner · 7 September 2020UTwente is responsible for developing imaging software and robot control for the OCT catheter as part of the OPOost-subsidized Next Gen In-Vivo Cancer Diagnostics project, enabling physician-independent and reproducible diagnostic results.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• NinePoint Medical: NinePoint Medical develops the NvisionVLE Imaging System, an optical coherence tomography-based probe for in vivo cross-sectional tissue imaging during endoscopy. Directly comparable to Scinvivo because both offer probe-based OCT optical biopsy platforms intended for real-time subsurface tissue visualization in endoscopic/cystoscopic procedures.
• Mauna Kea Technologies: Mauna Kea Technologies' Cellvizio is a probe-based confocal laser endomicroscopy platform that provides real-time in vivo cellular-level imaging during endoscopy. Comparable to Scinvivo as a competing optical biopsy modality integrated with endoscopic workflows in GI and pulmonary applications, serving similar clinical use cases.
• Michelson Diagnostics: Michelson Diagnostics develops multi-beam OCT imaging systems (VivoSight) for clinical dermatology, cervical, and surgical applications. Comparable to Scinvivo as a clinical OCT platform company translating the same underlying technology into clinical tissue imaging probes.

Broad incumbents

• Heidelberg Engineering: Heidelberg Engineering is a leading manufacturer of OCT systems, predominantly for ophthalmology but also active in research and surgical OCT. Comparable as a deep OCT specialist whose surgical/research product lines overlap with Scinvivo's forward-looking catheter applications.
• Karl Storz: Karl Storz is one of the world's largest manufacturers of endoscopes and urology visualization systems, including cystoscopes used in the very procedures Scinvivo targets. Comparable as the dominant incumbent in the urology endoscopy channel Scinvivo must access to commercialize.
• Olympus Corporation: Olympus is a global leader in endoscopic and urology imaging systems, with a large installed base of cystoscopes and broad R&D in minimally invasive visualization. Comparable as the most significant incumbent whose urology franchise Scinvivo would complement or compete against.
• Stryker: Stryker is a global medical device company with a meaningful urology and surgical imaging portfolio. Comparable as a large incumbent medtech where Scinvivo's former CFO spent 20+ years and a likely strategic acquirer or distribution partner for novel urology imaging.
• Carl Zeiss Meditec: Carl Zeiss Meditec is a global medical technology company specializing in ophthalmology, microsurgery, and intraoperative imaging solutions. Comparable as a broad incumbent with deep optics and OCT heritage that could expand into urology imaging.

Emerging players

• Lumicell: Lumicell is developing fluorescence-guided intraoperative imaging systems for cancer detection during surgery. Comparable as an emerging optical/cancer imaging company targeting intra-procedural tumor visualization in oncology workflows, overlapping with Scinvivo's surgical-navigation extension.
• OnLume: OnLume is developing fluorescence-guided surgery imaging platforms for real-time intraoperative visualization of tissue and perfusion. Comparable as an emerging optical imaging company addressing intraoperative cancer detection, sharing a similar trajectory toward surgical oncology visualization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scinvivo